What we do

Our platforms bridge your organizational and expertise gaps as long as you need it, empowering you to concentrate on the launch and move at XCLR8ED speed, from the clinic to market entry to lifecycle management while minimizing financial risks. Worldwide.

With the world’s leading scientists on board (>400 publications) we have access to main stakeholders of rare disease ecosystems, we evaluate & validate the REAL market sizes and consult & execute commercialization globally. subrosa OmicsAI identifies patients early, secure their treatment & adherence, also through Early Access Programs to leave no patient behind.

subrosa OmicsAI’s unique clinical patient identification programs are built on our proprietary global repositories of rare disease patients — genetically confirmed. “Unseen” patients are detected years earlier than today’s standards, hitting a precisely calculated success rate. Not estimated, data-driven calculated. Proven in more than 40 worldwide published programs.

subrosa Group’s recruiters are specialized in niche clinical, medical, and commercial profiles that rare disease, biotech, and especially startup companies require. With more than 2,800 executive and 3,600+ talent placements, we are recognized for our decades‑deep relationships with the right individuals—and the ability to secure their commitment to your organization.